|
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). |
|
|
Honoraria - Genentech/Roche; Merck; Millennium; Seagen |
Consulting or Advisory Role - Genentech/Roche; Merck; Seagen |
Speakers' Bureau - Genentech/Roche; Millennium; Seagen |
Research Funding - Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Merck; Seagen |
|
|
Honoraria - Research to Practice; WebMD |
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Seagen (Inst); Trillium Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - HERON; New York cancer specialists |
Leadership - New York Cancer Specialists |
|
Consulting or Advisory Role - HERON |
|
Travel, Accommodations, Expenses - HERON |
|
|
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Novartis; Pfizer; Takeda |
Research Funding - Celgene; Roche |
|
|
Consulting or Advisory Role - Celgene; Janssen; Takeda |
|
|
Consulting or Advisory Role - MorphoSys; Novartis; Sandoz |
Research Funding - Abbvie; AstraZeneca; Bayer; Celltrion; Gilead Sciences; Janssen; Merck; MorphoSys; Novartis; Roche; Sandoz; Takeda |
|
|
No Relationships to Disclose |
|
|
Expert Testimony - Celgene; Janssen; Roche |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Gilead Sciences; Janssen; Mundipharma; Roche/Genentech; SERVIER |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Novartis; NOvimmune; Roche/Genentech |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Employment - Celerion; Pfizer; PPD |
Research Funding - Pfizer |
|
|
|
Stock and Other Ownership Interests - Exelixis; Kite, a Gilead company; Mirati Therapeutics; Pfizer; Sunesis Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Exelixis |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - Gilead Sciences; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Gilead Sciences; Pfizer; Roche; Takeda |
Speakers' Bureau - Roche; Takeda |
Research Funding - AstraZeneca; Celgene; Onyx |
Travel, Accommodations, Expenses - Takeda |